Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3

NCT04637282 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Neuronal Ceroid Lipofuscinosis

Interventions

DRUG: PLX-200
DRUG: Placebo

Sponsor

Polaryx Therapeutics, Inc.